Literature DB >> 28442312

Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome.

Elie Azoulay1, Paul Knoebl2, José Garnacho-Montero3, Katerina Rusinova4, Gennadii Galstian5, Philippe Eggimann6, Fekri Abroug7, Dominique Benoit8, Michael von Bergwelt-Baildon9, Julia Wendon10, Marie Scully11.   

Abstract

A typical hemolytic uremic syndrome (aHUS) presents similarly to thrombotic thrombocytopenic purpura (TTP) and other causes or conditions with thrombotic microangiopathy (TMA), such as disseminated intravascular coagulation or sepsis. Similarity in clinical presentation may hinder diagnosis and optimal treatment selection in the urgent setting in the ICU. However, there is currently no consensus on the diagnosis or treatment of aHUS for ICU specialists. This review aims to summarize available data on the diagnosis and treatment strategies of aHUS in the ICU to enhance the understanding of aHUS diagnosis and outcomes in patients managed in the ICU. To this end, a review of the recent literature (January 2009-March 2016) was performed to select the most relevant articles for ICU physicians. Based on the paucity of adult aHUS cases overall and within the ICU, no specific recommendations could be formally graded for the critical care setting. However, we recognize a core set of skills required by intensivists for diagnosing and managing patients with aHUS: recognizing thrombotic microangiopathies, differentiating aHUS from related conditions, recognizing involvement of other organ systems, understanding the pathophysiology of aHUS, knowing the diagnostic workup and relevant outcomes in critically ill patients with aHUS, and knowing the standard of care for patients with aHUS based on available data and guidelines. In conclusion, managing critically ill patients with aHUS requires basic skills that, in the absence of sufficient data from patients treated within the ICU, can be gleaned from an increasingly relevant literature outside the ICU. More data on critically ill patients with aHUS are needed to validate these conclusions within the ICU setting.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  atypical hemolytic uremic syndrome; eculizumab; intensive care; organ failure; plasma exchange; thrombocytopenia; thrombotic microangiopathy

Mesh:

Substances:

Year:  2017        PMID: 28442312     DOI: 10.1016/j.chest.2017.03.055

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Quetiapine-induced thrombotic microangiopathy in a patient on maintenance dialysis.

Authors:  Miki Takahashi; Akihito Deguchi; Hiromu Nishihara; Mea Asou; Tomohiko Asakawa; Makoto Araki
Journal:  CEN Case Rep       Date:  2020-09-27

2.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

Review 3.  The unique characteristics of COVID-19 coagulopathy.

Authors:  Toshiaki Iba; Jerrold H Levy; Jean Marie Connors; Theodore E Warkentin; Jecko Thachil; Marcel Levi
Journal:  Crit Care       Date:  2020-06-18       Impact factor: 9.097

4.  Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase.

Authors:  Satoko Sakurai; Hideki Kato; Yoko Yoshida; Yuka Sugawara; Madoka Fujisawa; Atsushi Yasumoto; Masanori Matsumoto; Yoshihiro Fujimura; Yutaka Yatomi; Masaomi Nangaku
Journal:  J Atheroscler Thromb       Date:  2019-09-04       Impact factor: 4.928

Review 5.  Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome.

Authors:  Hajeong Lee; Eunjeong Kang; Hee Gyung Kang; Young Hoon Kim; Jin Seok Kim; Hee-Jin Kim; Kyung Chul Moon; Tae Hyun Ban; Se Won Oh; Sang Kyung Jo; Heeyeon Cho; Bum Soon Choi; Junshik Hong; Hae Il Cheong; Doyeun Oh
Journal:  Korean J Intern Med       Date:  2020-01-02       Impact factor: 2.884

6.  Thrombocytopenia in the ICU: disseminated intravascular coagulation and thrombotic microangiopathies-what intensivists need to know.

Authors:  Jean-Louis Vincent; Pedro Castro; Beverley J Hunt; Achim Jörres; Manuel Praga; Jose Rojas-Suarez; Eizo Watanabe
Journal:  Crit Care       Date:  2018-06-13       Impact factor: 9.097

Review 7.  Spinal Cord Ischemia Because of Microvascular Thrombosis in a Patient with Necrotizing Pancreatitis. Case Report and Literature Review.

Authors:  Olaf Patryk Dłuski; Aneta Agnieszka Durmaj; Maciej Kosieradzki; Maurycy Jonas; Benedykt Szczepankiewicz; Jarosław Czerwiński; Agata Adamczyk; Piotr Palczewski
Journal:  Am J Case Rep       Date:  2020-05-12

8.  Expert consensus on the diagnosis and treatment of thrombocytopenia in adult critical care patients in China.

Authors:  Jing-Chun Song; Shu-Yuan Liu; Feng Zhu; Ai-Qing Wen; Lin-Hao Ma; Wei-Qin Li; Jun Wu
Journal:  Mil Med Res       Date:  2020-04-03

9.  Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome.

Authors:  Michael Ryan; Bonnie M K Donato; William Irish; Christoph Gasteyger; Gilbert L'Italien; Jeffrey Laurence
Journal:  Pharmacoeconomics       Date:  2020-03       Impact factor: 4.981

10.  Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding.

Authors:  Yoko Fujita; Maho Terashita; Masahiko Yazawa; Yukitaka Yamasaki; Tomonori Imamura; Junichiro Kibayashi; Toshihiro Sawai; Yoshihiko Hidaka; Katsuki Ohtani; Norimitsu Inoue; Yugo Shibagaki
Journal:  Intern Med       Date:  2020-01-01       Impact factor: 1.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.